A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Phase of Trial: Phase II/III
Latest Information Update: 07 May 2017
At a glance
- Drugs Metformin (Primary) ; Carboplatin; Paclitaxel
- Indications Endometrial cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 23 Feb 2017 Status changed from suspended to recruiting.
- 09 Feb 2016 Status changed from recruiting to suspended as per ClinicalTrials.gov record.